A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489

Launched by PFIZER · Jul 9, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medicine called PF-07868489 to see how safe and well-tolerated it is over a longer period in people with pulmonary arterial hypertension (PAH). PAH is a condition where the blood pressure in the arteries going from the heart to the lungs is too high, making it harder for the heart to pump blood and potentially causing damage to the heart. This study is for people who have already taken part in an earlier trial with this medicine, allowing researchers to learn more about its long-term effects.

To be eligible, participants must be adults who completed the previous study with PF-07868489 without their PAH getting worse or needing to go to the hospital, and they should not have major health issues or certain conditions like liver-related lung problems. Participants will continue taking the medicine and will have regular check-ups, tests, and follow the study plan to help doctors understand how the medicine works over time. Both patients and doctors will know the treatment being given, as this is an open-label study. This trial is not recruiting yet but is open to adults of all genders who meet these requirements.

Gender

ALL

Eligibility criteria

• This study is seeking participants who are:
• • aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study.
• • willing and able to abide with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
• • do not have worsening or hospitalization for worsening PAH during the qualifying study.
• • not on placement for a surgery to replace any tissue or part of the body (transplant), and planned surgery for PAH.
• • do not have an ongoing major health issue in the qualifying study, which in the opinion of the study doctor could make the participant not qualify for this study.
• • not suffering from or in the past have suffered from hepato-pulmonary syndrome (liver-related lung problem).
• • not currently prescribed or taking medicines called as GLP-1 agonist.